Equities Analysts Issue Forecasts for CGTX FY2025 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at B. Riley issued their FY2025 earnings per share estimates for Cognition Therapeutics in a report released on Tuesday, November 26th. B. Riley analyst M. Mamtani anticipates that the company will post earnings of ($0.83) per share for the year. B. Riley has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.93) per share.

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald cut shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, July 30th. Chardan Capital reissued a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research note on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Cognition Therapeutics in a research report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Cognition Therapeutics Price Performance

Shares of CGTX opened at $0.40 on Wednesday. The stock has a fifty day simple moving average of $0.48 and a two-hundred day simple moving average of $1.12. The company has a market capitalization of $16.81 million, a PE ratio of -0.42 and a beta of 1.34. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95.

Institutional Investors Weigh In On Cognition Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in shares of Cognition Therapeutics in the 3rd quarter worth approximately $27,000. Sigma Planning Corp lifted its stake in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares in the last quarter. CM Management LLC boosted its position in shares of Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after buying an additional 25,000 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after buying an additional 24,050 shares in the last quarter. Finally, Bangor Savings Bank grew its stake in shares of Cognition Therapeutics by 41.6% in the second quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares in the last quarter. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.